N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants
Phase 2 N=33 Radiotherapy for Solid Tumor Spine Metastases
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
N/A N=36 Stereotactic Body Radiotherapy for Spine Tumors
Spinal Metastases · Vertebral Metastases · Benign Spinal Tumors
Primary: Initial Symptom Control — 3; 28; 3; 27 Participants
Phase 3 N=261 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Breast Cancer · Lung Cancer · Metastatic Cancer
Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844
N/A N=51 Spinery® A Novel Radio-Frequency Tumor Ablation Device for Spine Metastatic Tumors
Vertebral Metastasis
Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…
Phase 2 N=11 Zoledronate With Atorvastatin in Renal Cell Carcinoma
Kidney Cancer · Renal Cell Carcinoma
Primary: Median Time to First Skeletal-related Event — 9 months
Phase 2 N=44 S0916, MLN1202 in Treating Patients With Bone Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: uNTX Response Rate at 43 Days — 14 percentage of participants
Phase 3 N=46 Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Metastatic Cancer · Pain
Primary: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II) — 39; 37 Participants
N/A N=69 Dorsal Root Ganglion Thermal Radiofrequency Versus Pulsed Radiofrequency for Metastatic Pain in Thoracic Vertebral Body
Bone Neoplasm,Malignant Vertebral Column Thoracic Secondary
Primary: The European Organisation for Research and Treatment of Cancer (EORTC) Questionnaire to Measure Change in the Intensity of Pain QLQ-C30 — 41.30; 51.08; 38.76; 42.48…
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 3 N=437 A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Phase 2 N=71 Evaluation of Single Session Stereotactic Body Radiotherapy
Spinal Neoplasms
Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants
Phase 2 N=29 BN Brachyury and Radiation in Chordoma
Chordoma
Primary: Objective Response Rate (ORR) — 7.7 percentage of subjects with OR
N/A N=24 Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
Melanoma · Metastatic Malignant Neoplasm in the Spine · Renal Cell Carcinoma
Primary: Distance Between the Gross Disease and Spinal Cord (Cord-disease Distance, CDD) of at Least 3mm After Treatment. — 1; 14 Participants
Phase 2 N=12 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Phase 2 N=59 Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Brain Tumors · Osteoporosis · Central Nervous System(CNS)Malignancies
Primary: Percent of Patients With Change in Combined Bone Mass Density T-score <= -0.5. — 3.7; 10.5 percentage of patients
N/A N=102 Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
Phase 2 N=17 Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
Multiple Myeloma
Primary: Bone Mineral Density (BMD) — 0.14; -2.68 T-scores
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Phase 3 N=74 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Percentage Change in Bone Mineral Density (BMD) T-Score From Baseline to 12 Months — 0.08; -0.09 Percentage Change of BMD
Phase 3 N=48 Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
Bone Marrow Edema
Primary: Reduction of the Edema Area — 64.53; 23.97 percentage of edema volume — p==0.006
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=115 ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
Phase 2 N=60 To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370
Phase 2 N=11 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Sarcoma
Primary: Tumor Response — 10 participants
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
N/A N=81 Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus
Humerus Fracture Metastatic Bone Disease
Primary: Change in Pain — -52.7 units on a scale — p=0.615
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
N/A N=850 Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
Metastatic Cancer · Pain
Primary: Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment — 28.0; 32.0 percentage of participants — p=0.03